首页 >
法规速递
-
国家药监局关于发布免于进行临床试验体外诊断试剂目录（2025年）的通告（2025年第23号）-2025/6/24
2025-06-24查看详情 > -
Document: IRIS guide for applicants - How to create, submit and manage IRIS applications, for industry and individual applicants-2025/7/25
2025-07-27查看详情 > -
Page: Union Product Database-2025/9/11
2025-09-12查看详情 > -
Document: Guide for rapporteurs and coordinators on the multinational assessment teams-2025/10/15
2025-10-16查看详情 > -
图解海报 | 《国家药监局关于深化化妆品监管改革促进产业高质量发展的意见》系列解读（四）-2025/11/20
2025-11-21查看详情 > -
Document: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure-2025/12/15
2025-12-16查看详情 > -
Page: Quality of medicines questions and answers: Part 2-2026/1/28
2026-01-29查看详情 > -
Document: Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)-2026/3/6
2026-03-09查看详情 > -
Document: Notices and alerts per role - CTIS Training Programme - Module 07-2026/4/7
2026-04-08查看详情 > -
国家药监局关于适用《M13A：口服固体速释制剂的生物等效性》国际人用药品注册技术协调会指导原则的公告（2026年第49号）-2026/5/20
2026-05-21查看详情 >
